Navigation Links
Clinical trial shows tongue-controlled wheelchair outperforms popular wheelchair navigation system
Date:11/27/2013

etter with the Tongue Drive System than with the sip-and-puff system. On average, the performance of 11 subjects with tetraplegia using the Tongue Drive System was three times faster than their performance with the sip-and-puff system, but with the same level of accuracy, even though more than half of the patients had years of daily experience with sip-and-puff technology.

"That was a very exciting finding," Ghovanloo said. "It attests to how quickly and accurately you can move your tongue."

The idea for piercing the tongue with the magnet was the inspiration of Anne Laumann, M.D., professor of dermatology at Feinberg and a lead investigator of the Northwestern trial. She had read about an early stage of Tongue Drive System using a glued-on tongue magnet. The problem was the magnet fell off after a few hours and aspiration of the loose magnet was a real danger to these users.

"Tongue piercing put to medical use who would have thought it? It is needed and it works!" Laumann said.

The experiments were repeated over five weeks for the able-bodied test group, and over six weeks for the tetraplegic group. All of the subjects with tetraplegia were able to complete the trial, which Ghovanloo called an "exciting" and "major finding."

The tetraplegic group was using the Tongue Drive System just one day each week, but their improvement in performance was dramatic.

"We saw a huge, very significant improvement in their performance from session one to session two," Ghovanloo said. "That's an indicator of how quickly people learn this."

Experiments on the Tongue Drive System to date have been done in the lab or hospital. In future studies, scientists will test how the Tongue Drive System performs outside of the controlled clinical environment. The research team hopes to test how patients maneuver with the Tongue Drive System in their homes and other environments.

The Tongue Drive System isn't quite ready
'/>"/>

Contact: Brett Israel
brett.israel@comm.gatech.edu
404-385-1933
Georgia Institute of Technology
Source:Eurekalert  

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Positive Clinical Study Results for BSPs HyperQ Technology
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
6. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
7. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
8. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical trial shows tongue-controlled wheelchair outperforms popular wheelchair navigation system
(Date:3/4/2015)... 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of innovative therapies ... today announced that it will release fourth quarter ... on Monday, March 9th, 2015. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on March ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... Miami, FL on March 10, 2015 at 1:05 ... Financial Officer, will provide a corporate overview. The ... corporate website at www.halozyme.com , and a recording will ... access the live webcast, please log on to Halozyme,s website ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... GERMANTOWN, Maryland and HILDEN, Germany ... QGEN ; Frankfurt , Prime Standard:,QIA) today announced ... Institute,for Product Quality (ifp), pursuant to which QIAGEN has ... by the Berlin -based specialized,laboratory center for food ...
... ... and industry leaders from around the globe to discuss pain management, preclinical and clinical development ... ... Pain Therapeutics Summit , set to take place on October 4th-5th, 2010 in Philadelphia, has ...
... , May 25 Regado Biosciences, Inc., ... aptamers with active control agents, today announced issuance of ... new patent includes coverage for RB007, the modulator or ... REG1 and REG2 anticoagulation systems.  The allowed claims in ...
Cached Biology Technology:QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 2QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 3QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 4QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 5QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 6QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests 7Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit 2Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems 2Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems 3
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... may not be the only organisms endangered by some food ... health risks to humans who eat meat from chickens that ... the April 9 issue of Chemical & Engineering News, the ... Roxarsone, the most common arsenic-based additive used in chicken feed, ...
... As people age, they may have to exercise even harder ... suggestion of a report in the February issue of the ... signal that gives muscles a kind of metabolic boost in ... researchers found that so-called AMP-activated protein kinase (AMPK) slows down ...
... to repair the human body, replacing defective and worn ... the body does not always accept such substitutes seamlessly. ... simply changing the surface texture of implants can dramatically ... materials. , Two recent experiments have focused on ...
Cached Biology News:Power-boosting signal in muscle declines with age 2Nanotextured implant materials: blending in, not fighting back 2Nanotextured implant materials: blending in, not fighting back 3
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
... GPS-M Mutagenesis System enables you to insert ... into,your target DNA by in vitro transposition. ... Tn7-based,transposon randomly into the DNA target. Target ... or purified,chromosomal DNA, depending on your interests ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: